{"classes":[{"categories":[{"measurements":[{"comment":"Could not be estimated due to the low number of events at the time of analysis","groupId":"OG000","lowerLimit":"5.6","upperLimit":"NA","value":"7.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Overall survival was assessed from the date the participant received the first infusion of blinatumomab until death from any cause or the date of the last follow-up.\n\nParticipants still alive at the data cut-off date were censored on the last documented visit date or the date of the last contact when the patient was last known to have been alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieved a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.\n\nThe initial dose was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 and for all subsequent cycles of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"MEDIAN","populationDescription":"All participants who received an infusion of blinatumomab","reportingStatus":"POSTED","timeFrame":"From first dose of blinatumomab until the data cut-off date; median observation time was 8.8 months.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}